Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Price History
|
Ratios
|
Insiders
Bullboard - Stock Discussion Forum
Xencor Inc
XNCR
Healthcare
Biotechnology
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibodies for the treatment of asthma and allergic diseases, autoimmune diseases, and cancer. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, neuromyelitis optica spectrum disororder; and Monjuvi for...
the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; and Sotrovimab that targets the SARS-CoV-2 virus. It develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; Vudalimab, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer; XmAb564, to treat autoimmune diseases; XmAb662, which is in Phase I clinical trial to treat patients with solid tumors; XmAb942, which is...
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Bullboard (NDAQ:XNCR)
New Post
View:
Posts & Comments
Threaded Posts
(10)
•••
MikeTester
X
Post by
MikeTester
on Jan 24, 2025 3:30pm
Xencor (XNCR): Pioneering Engineered Antibodies for the Trea
Looks like a solid play in the biotech space. XNCR has some interesting antibody tech with multiple clinical-stage candidates in oncology and autoimmune diseases. Cash position of $754.7M gives them
...more
(10)
•••
MikeTester
X
Post by
MikeTester
on Aug 02, 2024 5:24am
Xencor, Inc. (NASDAQ:XNCR): Advancing a Robust Bispecific Pi
https://beyondspx.com/2024/08/01/xencor-inc-nasdaqxncr-advancing-a-robust-bispecific-pipeline-with-promising-prostate-cancer-data/
(6)
•••
ScarletteBourne
X
Post by
ScarletteBourne
on Nov 18, 2021 9:15pm
🎥📰Anthony Durkacz on Building a Turnaround at FSD Pharma📣
(6)
•••
ScarletteBourne
X
Post by
ScarletteBourne
on Nov 17, 2021 10:05am
🎉📣FSD Pharma's Research and Clinical Advisory Board📢
Dr. Eleanor N. Fish, a world-renowned immunologist and cytokine expert, has been appointed to FSD Pharma's Research and Clinical Advisory Board. FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA
...more
(6)
•••
ScarletteBourne
X
Post by
ScarletteBourne
on Nov 10, 2021 2:14am
📣FSD Pharma:Agreement Signed With Covar Pharmaceuticals📢📣
(6)
•••
ScarletteBourne
X
Post by
ScarletteBourne
on Oct 30, 2021 10:25am
📢📣FSD Pharma forms agreement with Covar Pharmaceuticals 📢
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.
Featured News Links
Global Currency Shifts Are Reshaping Commodities. Learn How. Secure Your Seat at VRIC 2026
Pinnacle Provides Progress Update for El Potrero Gold-Silver Project
Allied Critical Metals Announces Receipt of Environmental Permit for the Borralha Tungsten Project in Portugal
Team Spotlight: Every discovery begins with the people behind it
Sranan Gold Reports 11 M Grading 7.33 g/t Gold Including 4 M at 14.59 g/t Gold
Podcasts